This study is designed to assess the effect of renal impairment on the pharmacokinetics, safety and tolerability of udenafil in subjects with renal impairment compared to healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
27
100mg Single Oral Dose of
Asan Medical Center
Seoul, South Korea
Pharmacokinetics (AUC and Cmax)
Time frame: up to 48 hours
Safety
Time frame: up to 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.